WO2005017207A3 - Methods and compositions for detecting colon cancers - Google Patents

Methods and compositions for detecting colon cancers Download PDF

Info

Publication number
WO2005017207A3
WO2005017207A3 PCT/US2004/026478 US2004026478W WO2005017207A3 WO 2005017207 A3 WO2005017207 A3 WO 2005017207A3 US 2004026478 W US2004026478 W US 2004026478W WO 2005017207 A3 WO2005017207 A3 WO 2005017207A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
colon cancers
detecting colon
vimentin
Prior art date
Application number
PCT/US2004/026478
Other languages
French (fr)
Other versions
WO2005017207A2 (en
Inventor
Sanford D Markowitz
Original Assignee
Univ Case Western Reserve
Sanford D Markowitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve, Sanford D Markowitz filed Critical Univ Case Western Reserve
Priority to JP2006523432A priority Critical patent/JP4781267B2/en
Priority to CA2535910A priority patent/CA2535910C/en
Priority to EP04781201.1A priority patent/EP1660683B1/en
Publication of WO2005017207A2 publication Critical patent/WO2005017207A2/en
Publication of WO2005017207A3 publication Critical patent/WO2005017207A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

This application describes methods and compositions for detecting and treating vimentin-associated neoplasia. Differential methylation of the vimentin nucleotide sequences has been observed in vimentin-associated neoplasia such as colon neoplasia.
PCT/US2004/026478 2003-08-14 2004-08-16 Methods and compositions for detecting colon cancers WO2005017207A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006523432A JP4781267B2 (en) 2003-08-14 2004-08-16 Method and composition for detecting colorectal cancer
CA2535910A CA2535910C (en) 2003-08-14 2004-08-16 Methods and compositions for detecting colon cancers
EP04781201.1A EP1660683B1 (en) 2003-08-14 2004-08-16 Methods and compositions for detecting colon cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49506403P 2003-08-14 2003-08-14
US60/495,064 2003-08-14

Publications (2)

Publication Number Publication Date
WO2005017207A2 WO2005017207A2 (en) 2005-02-24
WO2005017207A3 true WO2005017207A3 (en) 2005-10-27

Family

ID=34193270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/026478 WO2005017207A2 (en) 2003-08-14 2004-08-16 Methods and compositions for detecting colon cancers

Country Status (5)

Country Link
US (4) US7485420B2 (en)
EP (1) EP1660683B1 (en)
JP (2) JP4781267B2 (en)
CA (1) CA2535910C (en)
WO (1) WO2005017207A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845991B2 (en) 2009-02-03 2023-12-19 Exact Sciences Corporation Fecal sample processing and analysis comprising detection of blood
US11970746B2 (en) 2010-02-03 2024-04-30 Exact Sciences Corporation Fecal sample processing and analysis comprising detection of blood

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003213107A1 (en) 2002-02-15 2003-09-09 Exact Sciences Corporation Methods for analysis of molecular events
JP2006501153A (en) * 2002-05-23 2006-01-12 パーデュー・リサーチ・ファウンデーション Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target
US8415100B2 (en) 2003-08-14 2013-04-09 Case Western Reserve University Methods and compositions for detecting gastrointestinal and other cancers
EP1660683B1 (en) * 2003-08-14 2017-04-19 Case Western Reserve University Methods and compositions for detecting colon cancers
US20080241827A1 (en) * 2004-05-10 2008-10-02 Exact Sciences Corporation Methods For Detecting A Mutant Nucleic Acid
WO2006026654A2 (en) 2004-08-27 2006-03-09 Exact Sciences Corporation Method for detecting a recombinant event
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
WO2006094149A2 (en) * 2005-03-01 2006-09-08 Exact Sciences Corporation Methods and compositions for detecting adenoma
WO2007044071A2 (en) * 2005-04-21 2007-04-19 Exact Sciences Corporation Analysis of heterogeneous nucleic acid samples
US9556430B2 (en) * 2005-05-27 2017-01-31 Dana-Farber Cancer Institute, Inc. Gene methylation and expression
EP2215257A4 (en) * 2007-10-23 2010-12-01 Clinical Genomics Pty Ltd A method of diagnosing neoplasms - ii
US20120034605A1 (en) 2009-04-03 2012-02-09 A&T Corporation Method for detection of colorectal tumor
EP3327139A1 (en) * 2009-04-06 2018-05-30 The Johns Hopkins University Digital quantification of dna methylation
US8642271B2 (en) * 2009-08-27 2014-02-04 Case Western Reserve University Aberrant methylation of C6Orf150 DNA sequences in human colorectal cancer
US20130012410A1 (en) * 2010-03-29 2013-01-10 Mayo Foundation For Medical Education And Research Methods and materials for detecting colorectal cancer and adenoma
WO2012052844A1 (en) * 2010-10-19 2012-04-26 Oslo Universitetssykehus Hf Methods and biomarkers for detection of bladder cancer
US8916344B2 (en) * 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
JP2014519310A (en) 2011-02-02 2014-08-14 エクザクト サイエンシーズ コーポレイション Digital sequence analysis of DNA methylation
GB201107466D0 (en) 2011-05-05 2011-06-15 Loktionov Alexandre Device and method for non-invasive collection of colorectal mucocellular layer and disease detection
US20150072866A1 (en) * 2012-03-20 2015-03-12 Exact Sciences Corporation Marker panel for detecting cancer
CA2902916C (en) 2013-03-14 2018-08-28 Mayo Foundation For Medical Education And Research Detecting neoplasm
US10253358B2 (en) 2013-11-04 2019-04-09 Exact Sciences Development Company, Llc Multiple-control calibrators for DNA quantitation
WO2015089422A1 (en) 2013-12-12 2015-06-18 Case Western Reserve University Device for collecting a biological sample
WO2015095689A1 (en) 2013-12-19 2015-06-25 Exact Sciences Corporation Synthetic nucleic acid control molecules
EP3126519A4 (en) 2014-03-31 2018-01-17 Mayo Foundation for Medical Education and Research Detecting colorectal neoplasm
WO2016085944A1 (en) * 2014-11-24 2016-06-02 Case Western Reserve University Diagnostic and therapeutic targeting of dnmt-1 associated rna in human cancer
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
AU2016315924B2 (en) 2015-08-31 2022-08-25 Exact Sciences Corporation Detecting gastric neoplasm
WO2017180886A1 (en) 2016-04-14 2017-10-19 Mayo Foundation For Medical Education And Research Detecting pancreatic high-grade dysplasia
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
AU2017292668B2 (en) * 2016-07-06 2023-11-09 Case Western Reserve University Methods and compositions for detecting esophageal neoplasias and/or metaplasias in the esophagus
CN110431241B (en) 2017-02-28 2024-04-19 梅约医学教育与研究基金会 Detection of prostate cancer
US10975443B2 (en) 2017-11-30 2021-04-13 Mayo Foundation For Medical Education And Research Detecting breast cancer
AU2019351130A1 (en) 2018-09-27 2021-04-08 Grail, Llc Methylation markers and targeted methylation probe panel

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148327A1 (en) * 2000-04-06 2003-08-07 Alexander Olek Diagnosis of diseases associated with metastasis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853975A (en) * 1994-08-23 1998-12-29 Millennium Pharmaceuticals, Inc. Methods for identifying compositions for the treatment of body weight disorders, including obesity
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
JP4151751B2 (en) * 1999-07-22 2008-09-17 第一三共株式会社 New bicyclonucleoside analogues
DE10019058A1 (en) * 2000-04-06 2001-12-20 Epigenomics Ag Designing primers and probes for analyzing diseases associated with cytosine methylation state e.g. arthritis, cancer, aging, arteriosclerosis comprising fragments of chemically modified genes associated with cell cycle
ES2299520T3 (en) 2000-09-01 2008-06-01 Epigenomics Ag PROCEDURE FOR THE DETERMINATION OF THE DEGREE OF METHYLATION OF CERTAIN CITOSINES IN GENOMIC DNA IN THE SEQUENTIAL CONTEXT 5'-CPG-3 '.
AUPR142500A0 (en) * 2000-11-13 2000-12-07 Human Genetic Signatures Pty Ltd A peptide nucleic acid-based assay for the detection of specific nucleic acid sequences
DE10056802B4 (en) * 2000-11-14 2005-06-16 Epigenomics Ag Method for the detection of methylation conditions for toxicological diagnostics
EP1660683B1 (en) 2003-08-14 2017-04-19 Case Western Reserve University Methods and compositions for detecting colon cancers
GB0700374D0 (en) * 2007-01-09 2007-02-14 Oncomethylome Sciences S A NDRG family methylation markers
US7785772B2 (en) * 2007-01-23 2010-08-31 Mayo Foundation For Medical Education And Research Detecting methylated mammalian nucleic acid in stool

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148327A1 (en) * 2000-04-06 2003-08-07 Alexander Olek Diagnosis of diseases associated with metastasis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DOMAGALA W ET AL: "VIMENTIN IS PREFERENTIALLY EXPRESSED IN HUMAN BREAST CARCINOMAS WITH LOW ESTROGEN RECEPTOR AND HIGH KI-67 GROWTH FRACTION", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 136, no. 1, January 1990 (1990-01-01), pages 219 - 227, XP008006515, ISSN: 0002-9440 *
EDEN SHARON ET AL: "Role of DNA methylation in the regulation of transcription", CURRENT OPINION IN GENETICS AND DEVELOPMENT, vol. 4, no. 2, 1994, pages 255 - 259, XP009044081, ISSN: 0959-437X *
IZMAILOVA E S ET AL: "A GC-box is required for expression of the human vimentin gene", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 235, no. 1-2, 22 July 1999 (1999-07-22), pages 69 - 75, XP004174740, ISSN: 0378-1119 *
LANGA FRANCINA ET AL: "Teratocarcinomas induced by embryonic stem (ES) cells lacking vimentin: An approach to study the role of vimentin in tumorigenesis", JOURNAL OF CELL SCIENCE, vol. 113, no. 19, October 2000 (2000-10-01), pages 3463 - 3472, XP002318359, ISSN: 0021-9533 *
LI HUI ET AL: "SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 14, 8 July 2003 (2003-07-08), pages 8412 - 8417, XP001205249, ISSN: 0027-8424 *
PETKO ZSOLT ET AL: "Aberrantly methylated CDKN2A, MGMT and hMLH1 are biomarkers for colon adenomas and colon adenocarcinomas.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07-01), & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, pages 698, XP001205250, ISSN: 0197-016X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845991B2 (en) 2009-02-03 2023-12-19 Exact Sciences Corporation Fecal sample processing and analysis comprising detection of blood
US11970746B2 (en) 2010-02-03 2024-04-30 Exact Sciences Corporation Fecal sample processing and analysis comprising detection of blood

Also Published As

Publication number Publication date
EP1660683B1 (en) 2017-04-19
JP5575053B2 (en) 2014-08-20
CA2535910A1 (en) 2005-02-24
JP4781267B2 (en) 2011-09-28
US20100209906A1 (en) 2010-08-19
EP1660683A2 (en) 2006-05-31
US7964353B2 (en) 2011-06-21
US20110217708A1 (en) 2011-09-08
US20100009359A1 (en) 2010-01-14
US20050106593A1 (en) 2005-05-19
US8481707B2 (en) 2013-07-09
CA2535910C (en) 2016-04-26
JP2007502121A (en) 2007-02-08
WO2005017207A2 (en) 2005-02-24
JP2011200237A (en) 2011-10-13
US7485420B2 (en) 2009-02-03
US8221977B2 (en) 2012-07-17

Similar Documents

Publication Publication Date Title
WO2005017207A3 (en) Methods and compositions for detecting colon cancers
WO2003031932A3 (en) Methods and compositions for detecting colon cancers
WO2001036685A3 (en) Differential gene expression in cancer
WO2005027962A3 (en) 4’-thionucleosides and oligomeric compounds
WO2001096584A3 (en) Materials and methods for the control of nematodes
EP1750771A4 (en) Pancreatic islet microrna and methods for inhibiting same
EP2505668A3 (en) MicroRNA-based methods for the diagnosis of colon, lung, and pancreatic cancer
WO2007009755A3 (en) Compositions and methods for cancer diagnostics comprising pan-cancer markers
EP1604013A4 (en) Aberrantly methylated genes in pancreatic cancer
EP1691842A4 (en) Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent
WO2003050243A3 (en) Novel genes encoding colon cancer antigens
WO2001052904A3 (en) Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides
MX276236B (en) Coating compositions containing reactive diluents and methods.
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
WO2004044160A3 (en) Muc1 interference rna compositions and methods derived therefrom
WO2004031402A3 (en) Methylation profile of cancer
WO2003035889A3 (en) Compositions and methods for bacteria detection
WO2004076623A3 (en) Rna-interference for znfn3a1-gene as a method for inhibiting cancer cell growth
AU2003252249A1 (en) Method of judging cancer based on the expression of homeobox gene
WO2004091484A3 (en) Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en­22-one 16-0-(2-0-4-methoxybenzoyl-beta-d-xylopyranosyl)-(1->3)-(2-0­acetyl-alpha-l-arabinopyranoside)] or osw-1 and its derivatives for cancer therapeutics
MXPA05008817A (en) Nucleotide lipid ester derivatives.
WO2004096021A3 (en) Global analysis of transposable elements as molecular markers of cancer
WO2004050834A3 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
AU2003256075A1 (en) Method for treating or preventing metastasis of colorectal cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006523432

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2535910

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2004781201

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004781201

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004781201

Country of ref document: EP